Home » Cardiovascular » ARRIVE Trial: Aspirin for Primary Prevention in Adults at Moderate Cardiovascular Risk

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

ARRIVE Trial: Aspirin for Primary Prevention in Adults at Moderate Cardiovascular Risk

 

2018, Effect of Aspirin in elderly at moderate CVD risk | LANCET

Subscribe via email